ArticleInternational journal of obesity (2005)2026
Integrative multi-omics analysis of DNA methylome and transcriptome in a tyrosine kinase inhibitor LPM4870108-induced rat model of obesity.
Article in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is a serious multifactorial disease that involves epigenetic mechanisms like DNA methylation. Tyrosine kinase inhibitors (TKIs), originally synthesized and approved for cancer therapy, have recently been linked to the regulation of obesity. We evaluated whether LPM4870108, a small-molecule TKI with antitumor efficacy, contributes to obesity via DNA methylation.
methodsLPM4870108 (TKI) was administered orally to rats at 0, 1.25, 2.5, or 5.0 mg/kg (for 28 days, twice daily). Body weights (BWs) and food intake were recorded daily. After 28 days of administration, ventromedial hypothalamus (VMH) tissues were collected for whole-genome transcriptomic and methylation sequencing to identify candidate genes. The mRNA expression and promoter methylation of candidate genes were analyzed by real-time RT-PCR and pyrosequencing, respectively. Protein levels of DNA methyltransferases (DNMTs) were determined by Western blot.
resultsLPM4870108 treatment substantially increased food intake and BW. Whole-genome transcriptomic and methylation profiling identified 415 differentially expressed genes (DEGs) and 124,935 differentially methylated regions (DMRs) within the VMH of LPM4870108-treated rats. The transcriptomic results were combined with whole-genome methylation sequencing data, followed by further verification via RT-PCR and pyrosequencing, through which the obesity-related candidate gene arginine vasopressin (AVP) was identified. Among all DEGs, AVP showed the most prominent change, with a negative association between its promoter methylation and mRNA expression level. Reduced protein expression of DNA methyltransferase 3A (DNMT3A) in the VMH was also detected in LPM4870108-treated rats.
conclusionsThese findings indicate that LPM4870108-stimulated hyperphagia and weight gain were associated with DNA hypomethylation and concomitant upregulation of the AVP gene. LPM4870108, tyrosine kinase inhibitors; VMH, ventromedial hypothalamus; RRBS, reduced representation bisulfite sequencing; AVP, arginine vasopressin; DNMT, DNA methyltransferases.
Identifiers
42432101What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.